^
Association details:
| Biomarker: | BRCA1 mutation |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | berzosertib (M6620) (ATR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors
Published date:
06/22/2020
Excerpt:
Forty patients were enrolled; 17 received M6620 monotherapy, which was safe and well tolerated...A patient with metastatic colorectal cancer harboring molecular aberrations, including ATM loss and an ARID1A mutation, achieved RECISTv1.1 complete response and maintained this response, with a progression-free survival of 29 months at last assessment.
DOI:
10.1200/JCO.19.02404
